Cochrane · systematic review · CD009992
Topical antifungal treatments for tinea cruris and tinea corporis
El‐Gohary, M, van Zuuren, EJ, Fedorowicz, Z, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
36
current version
GRADE rated
25
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 11 · 30.6%Very low 14 · 38.9%Low 11 · 30.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Terbinafine 1% cream/gel compared with placebo cream/gel for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy, or culture, or both. Treatment duration 1‐2 weeks Terbinafine 1% cream/gel vs placebo cream/gel | no estimate extracted | 7 studies · 330 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Clinical cure Resolution of clinical signs and symptoms. Treatment duration 1‐2 weeks Terbinafine 1% cream/gel vs placebo cream/gel | RR 4.51 [3.1, 6.56] | 5 studies · 273 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects Reported by investigators 'and' or 'or' participants Terbinafine 1% cream/gel vs placebo cream/gel | RR 0.43 [0.2, 0.92] | 7 studies · 469 participants | Very low Downgraded: risk of bias, imprecision |
Relapse or recurrence Evidence of clinical or mycological infection in previously cured participants Terbinafine 1% cream/gel vs placebo cream/gel | no estimate extracted | 3 studies · 168 participants | Low Downgraded: risk of bias, imprecision |
Participant‐judged cure Judgement of treatment as 'good' or 'very good' Terbinafine 1% cream/gel vs placebo cream/gel | RR 4.46 [3.16, 6.31] | 2 studies · 253 participants | Low Downgraded: risk of bias, imprecision |
Duration of treatment until clinical cure Not assessed Terbinafine 1% cream/gel vs placebo cream/gel | no estimate extracted | 0 studies · 0 participants | Ungraded |
Naftifine 1% cream once or twice daily compared with placebo cream once or twice daily for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy and culture. Treatment duration 2‐4 weeks Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | RR 2.38 [1.8, 3.14] | 3 studies · 187 participants | Low Downgraded: risk of bias, imprecision |
Clinical cure Resolution of clinical signs and symptoms at least 2 weeks from start of treatment Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | RR 2.42 [1.41, 4.16] | 1 study · 63 participants | Low Downgraded: imprecision |
Adverse effects Reported by investigators 'and' or 'or' participants Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | RR 0.44 [0.13, 1.57] | 3 studies · 195 participants | Very low Downgraded: risk of bias, imprecision |
Relapse or recurrence Evidence of clinical or mycological infection in previously cured participants Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | RR 0.07 [0, 1.25] | 1 study · 44 participants | Low Downgraded: imprecision |
Participant‐judged cure Not assessed Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | no estimate extracted | 0 studies · 0 participants | Ungraded |
Duration of treatment until clinical cure Not assessed Naftifine 1% cream once or twice daily vs placebo cream once or twice daily | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azoles compared with allylamines for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy and culture. Treatment duration 1‐7 weeks Azoles vs allylamines | no estimate extracted | 7 studies · 638 participants | Very low Downgraded: risk of bias, inconsistency |
Clinical cure Resolution of clinical signs and symptoms at least 2 weeks from the start of treatment. Treatment duration 1‐7 weeks Azoles vs allylamines | no estimate extracted | 6 studies · 605 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse effects Reported by investigators 'and' or 'or' participants Azoles vs allylamines | RR 0.7 [0.18, 2.68] | 5 studies · 386 participants | Very low Downgraded: risk of bias, imprecision |
Relapse or recurrence Evidence of clinical and mycological relapse after the end of treatment. Assessed in 3 studies Azoles vs allylamines | RR 2.33 [0.21, 26.23] | 3 studies · 105 participants | Very low Downgraded: risk of bias |
Participant‐judged cure Not assessed Azoles vs allylamines | no estimate extracted | 0 studies · 0 participants | Ungraded |
Duration of treatment until clinical cure Scale from: 21 to 77 Azoles vs allylamines | no estimate extracted | 1 study · 7 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Azoles compared with moderate‐potent corticosteroid/azole combinations for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy and culture. Treatment duration 2‐3 weeks Azoles vs moderate‐potent corticosteroid/azole combinations | RR 0.99 [0.93, 1.05] | 6 studies · 625 participants | Low Downgraded: risk of bias |
Clinical cure (immediately at end of treatment) Resolution of clinical signs and symptoms at least 2 weeks from the start of treatment Azoles vs moderate‐potent corticosteroid/azole combinations | RR 0.67 [0.53, 0.84] | 4 studies · 353 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects Reported by investigators 'and' or 'or' participants Azoles vs moderate‐potent corticosteroid/azole combinations | RR 1.36 [0.68, 2.69] | 5 studies · 668 participants | Very low Downgraded: risk of bias, imprecision |
Relapse or recurrence Not assessed Azoles vs moderate‐potent corticosteroid/azole combinations | no estimate extracted | 0 studies · 0 participants | Ungraded |
Participant‐judged cure 4‐point symptom score scale Azoles vs moderate‐potent corticosteroid/azole combinations | no estimate extracted | 0 studies · 1 participants | Low Downgraded: risk of bias |
Duration of treatment until clinical cure Not assessed Azoles vs moderate‐potent corticosteroid/azole combinations | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azoles compared with benzylamines for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy and culture. Treatment duration 2‐4 weeks Azoles vs benzylamines | RR 1.01 [0.94, 1.07] | 3 studies · 219 participants | Low Downgraded: risk of bias |
Clinical cure Resolution of clinical signs and symptoms at least 2 weeks from the start of treatment Azoles vs benzylamines | no estimate extracted | 2 studies · 169 participants | Low Downgraded: inconsistency |
Adverse effects Reported by investigators 'and' or 'or' participants Azoles vs benzylamines | RR 0.85 [0.41, 1.76] | 3 studies · 263 participants | Very low Downgraded: risk of bias, imprecision |
Relapse or recurrence Evidence of clinical or mycological disease after successful treatment Azoles vs benzylamines | RR 1.84 [0.35, 9.6] | 3 studies · 215 participants | Very low Downgraded: risk of bias |
Participant‐judged cure Not assessed Azoles vs benzylamines | no estimate extracted | 0 studies · 0 participants | Ungraded |
Duration of treatment until clinical cure Not assessed Azoles vs benzylamines | no estimate extracted | 0 studies · 0 participants | Ungraded |
Azoles versus placebo for tinea cruris and tinea corporis
Population: patients with tinea cruris and tinea corporis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mycological cure Negative KOH microscopy and culture. Treatment duration 2‐4 weeks Azoles vs placebo | no estimate extracted | 4 studies · 490 participants | Very low Downgraded: risk of bias, inconsistency |
Clinical cure Resolution of clinical signs and symptoms. Treatment duration 2‐4 weeks Azoles vs placebo | no estimate extracted | 3 studies · 336 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse effects Reported by investigators 'and' or 'or' participants Azoles vs placebo | RR 0.25 [0.06, 0.99] | 3 studies · 266 participants | Very low Downgraded: risk of bias |
Relapse or recurrence Not assessed Azoles vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Participant‐judged cure Not assessed Azoles vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Duration of treatment until clinical cure Not assessed Azoles vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |